GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (FRA:NB3) » Definitions » Piotroski F-Score

Neurocrine Biosciences (FRA:NB3) Piotroski F-Score : 5 (As of Mar. 03, 2025)


View and export this data going back to 1996. Start your Free Trial

What is Neurocrine Biosciences Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Neurocrine Biosciences has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Neurocrine Biosciences's Piotroski F-Score or its related term are showing as below:

FRA:NB3' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 7
Current: 5

During the past 13 years, the highest Piotroski F-Score of Neurocrine Biosciences was 7. The lowest was 2. And the median was 5.


Neurocrine Biosciences Piotroski F-Score Historical Data

The historical data trend for Neurocrine Biosciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Piotroski F-Score Chart

Neurocrine Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 4.00 6.00 5.00 5.00

Neurocrine Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 6.00 6.00 6.00 5.00

Competitive Comparison of Neurocrine Biosciences's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurocrine Biosciences's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Net Income was 39.928 + 60.385 + 116.95 + 98.461 = €316 Mil.
Cash Flow from Operations was 119.876 + 60.013 + 142.358 + 231.588 = €554 Mil.
Revenue was 474.076 + 548.296 + 560.512 + 599.454 = €2,182 Mil.
Gross Profit was 467.176 + 539.749 + 553.304 + 590.572 = €2,151 Mil.
Average Total Assets from the begining of this year (Dec23)
to the end of this year (Dec24) was
(2981.534 + 3194.608 + 3070.345 + 3185.035 + 3551.359) / 5 = €3196.5762 Mil.
Total Assets at the begining of this year (Dec23) was €2,982 Mil.
Long-Term Debt & Capital Lease Obligation was €435 Mil.
Total Current Assets was €1,647 Mil.
Total Current Liabilities was €485 Mil.
Net Income was -71.544 + 88.147 + 77.865 + 135.441 = €230 Mil.

Revenue was 392.654 + 417.842 + 467.376 + 472.438 = €1,750 Mil.
Gross Profit was 384.715 + 407.228 + 456.881 + 464.644 = €1,713 Mil.
Average Total Assets from the begining of last year (Dec22)
to the end of last year (Dec23) was
(2236.053 + 2204.053 + 2411.891 + 2668.763 + 2981.534) / 5 = €2500.4588 Mil.
Total Assets at the begining of last year (Dec22) was €2,236 Mil.
Long-Term Debt & Capital Lease Obligation was €237 Mil.
Total Current Assets was €1,474 Mil.
Total Current Liabilities was €600 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Neurocrine Biosciences's current Net Income (TTM) was 316. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Neurocrine Biosciences's current Cash Flow from Operations (TTM) was 554. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec23)
=315.724/2981.534
=0.10589314

ROA (Last Year)=Net Income/Total Assets (Dec22)
=229.909/2236.053
=0.10281912

Neurocrine Biosciences's return on assets of this year was 0.10589314. Neurocrine Biosciences's return on assets of last year was 0.10281912. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Neurocrine Biosciences's current Net Income (TTM) was 316. Neurocrine Biosciences's current Cash Flow from Operations (TTM) was 554. ==> 554 > 316 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=434.621/3196.5762
=0.13596454

Gearing (Last Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=236.861/2500.4588
=0.09472702

Neurocrine Biosciences's gearing of this year was 0.13596454. Neurocrine Biosciences's gearing of last year was 0.09472702. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec24)=Total Current Assets/Total Current Liabilities
=1647.089/484.854
=3.39708242

Current Ratio (Last Year: Dec23)=Total Current Assets/Total Current Liabilities
=1473.619/600.452
=2.45418285

Neurocrine Biosciences's current ratio of this year was 3.39708242. Neurocrine Biosciences's current ratio of last year was 2.45418285. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Neurocrine Biosciences's number of shares in issue this year was 102.8. Neurocrine Biosciences's number of shares in issue last year was 102.2. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2150.801/2182.338
=0.98554898

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1713.468/1750.31
=0.97895116

Neurocrine Biosciences's gross margin of this year was 0.98554898. Neurocrine Biosciences's gross margin of last year was 0.97895116. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec23)
=2182.338/2981.534
=0.7319514

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec22)
=1750.31/2236.053
=0.78276767

Neurocrine Biosciences's asset turnover of this year was 0.7319514. Neurocrine Biosciences's asset turnover of last year was 0.78276767. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+1+0+1+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Neurocrine Biosciences has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Neurocrine Biosciences  (FRA:NB3) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Neurocrine Biosciences Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurocrine Biosciences Business Description

Traded in Other Exchanges
Address
6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Neurocrine Biosciences Headlines

No Headlines